{
  "documentMetadata": {
    "title": "Disseminated Gonococcal Infection",
    "lastUpdated": "2025-05-06",
    "sourceFile": "Gonorrhea_ Disseminated Gonococcal Infection.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Disseminated gonococcal infection, dermatitis-arthritis syndrome.",
        "Potential uncommon complications include perihepatitis (Fitzhugh-Curtis syndrome), endocarditis, and meningitis",
        "Patient often has no symptoms or findings of urethritis or cervicitis, but rectal or pharygeal culture or NAAT may be positive",
        "Culture genital and extra-genital locations.",
        "Arthritis often presents as tenosynovitis or monoarticular/asymmetric pauciarticular arthritis.",
        "Risk factor: terminal complement system deficiency: can be inherited or induced in patients given eculizumab for paroxysmal nocturnal hemoglobinuria (Clin Infect Dis 2019:69:596); absent terminal complement system also places patients at increased risk of meningococcemia.",
        "Differential diagnosis: Meningococcemia, RMSF, dengue"
      ]
    },
    {
      "type": "image",
      "imageData": {
        "src": "/home/ertwro/programming/pased_database/references/syndromes/musculoskeletal/joint/septic_arthritis_specific/Gonorrhea_ Disseminated Gonococcal Infection.pdf",
        "caption": ""
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Neisseria gonorrhoeae"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Ceftriaxone",
            "dose": "1 gm",
            "route": "IV",
            "frequency": "q24h"
          }
        ],
        "durationDetail": {
          "fixedDuration": "at least 7 days"
        }
      }
    },
    {
      "type": "list",
      "items": [
        "Use parenteral Ceftriaxone 1-2g q 12-24h for meningitis (10-14 days) or endocarditis (4 weeks) for full course",
        "Need in vitro susceptibility of the bloodstream isolate to guide potential switch to an oral cephalosporin (Cefixime 800 mg po bid) or fluoroquinolone (Ciprofloxacin 500 mg po bid)",
        "May need joint washout by orthopedics to minimize cartilage damage",
        "Can switch to po therapy 24-48h after substantial clinical improvement"
      ]
    },
    {
      "type": "paragraph",
      "text": "Formal infectious diseases consultation is suggested"
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Other 3rd generation cephalosporins can be substituted for ceftriaxone:"
      ]
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Cefotaxime",
            "dose": "1 gm",
            "route": "q8h IV",
            "frequency": "q8h"
          }
        ],
        "notes": "where available"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Ceftizoxime",
            "dose": "1 gm",
            "route": "q8h IV",
            "frequency": "q8h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Spectinomycin",
            "dose": "2 gm",
            "route": "q12 IM"
          }
        ],
        "notes": "for disseminated disease (available in Europe)"
      }
    },
    {
      "type": "list",
      "items": [
        "If severe allergy to cephalosporins, suggest ID consult to determine best alternative agents."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Fluoroquinolones may be effective if susceptible organism, but no clinical data with these agents.",
        "Clinically assess for possible associated meningitis/endocarditis.",
        "Spectinomycin: Recommended by European Guidelines for disseminated disease. U.S. distribution was discontinued in 2005 and is no longer recommended by the current CDC STD Guidelines.",
        "\"Step-down\" therapy should be avoided unless susceptibilities are known of patient's bloodstream isolate are known and demonstrate full activity of of an oral cephalosporin or fluoroquinolone",
        "All gonorrhea patients should be tested for HIV, syphilis, and Chlamydia",
        "Sexual partners should be evaluated",
        "Routine treatment for concomitant C. trachomatis no longer recommended in US for gonorrhea because of frequent selection of resistant organisms in CDC 2020 guidelines MMWR 69:1911. 2020 and CDC 2021 STD guidelines MMWR Recomm Rep 70 (RR-4):1 2021.",
        "Review of evidence for CDC guidelines: Clin Infect Dis 74:S95 2022"
      ]
    }
  ]
}